|
Powered by Cell Signaling Technology |
| Site Information |
|---|
| PYHFrAPsRIFWRTV SwissProt Entrez-Gene |
| Blast this site against: NCBI SwissProt PDB |
| Site Group ID: 5594501 |
| In vivo Characterization | |
|---|---|
| Methods used to characterize site in vivo: | |
| Disease tissue studied: | |
| Relevant cell line - cell type - tissue: | |
| Upstream Regulation | |
|---|---|
| Putative in vivo kinases: | |
| Kinases, in vitro: | |
| Treatments: | |
| Downstream Regulation | |
|---|---|
| Effects of modification on RPL13A: | |
| Effects of modification on biological processes: | |
| Induce interaction with: | |
| References | |
|---|---|
|
Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004 Curated Info |
|
|
Arif A, Chatterjee P, Moodt RA, Fox PL (2012) Heterotrimeric GAIT Complex Drives Transcript-Selective Translation Inhibition in Murine Macrophages. Mol Cell Biol 32, 5046-55
23071094 Curated Info |
|
|
Jia J, et al. (2012) Protection of Extraribosomal RPL13a by GAPDH and Dysregulation by S-Nitrosylation. Mol Cell 47, 656-63
22771119 Curated Info |
|
|
Mukhopadhyay R, et al. (2008) DAPK-ZIPK-L13a axis constitutes a negative-feedback module regulating inflammatory gene expression. Mol Cell 32, 371-82
18995835 Curated Info |
|
|
Possemato A (2008) CST Curation Set: 3770; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info |